ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 109 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 1.92 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $42,126,000 | -36.0% | 2,100,000 | -10.0% | 1.70% | -26.3% |
Q2 2023 | $65,842,140 | +30.7% | 2,334,000 | -20.3% | 2.30% | +37.6% |
Q1 2023 | $50,383,960 | -51.4% | 2,929,300 | -43.1% | 1.67% | -25.6% |
Q4 2022 | $103,721,000 | +13.4% | 5,150,000 | +21.9% | 2.25% | +20.8% |
Q3 2022 | $91,472,000 | -9.2% | 4,223,100 | +17.8% | 1.86% | -19.6% |
Q2 2022 | $100,763,000 | -31.3% | 3,585,881 | +12.9% | 2.31% | -24.2% |
Q1 2022 | $146,587,000 | -35.8% | 3,176,999 | +17.0% | 3.05% | -36.9% |
Q4 2021 | $228,223,000 | +37.3% | 2,715,000 | +8.9% | 4.84% | +31.5% |
Q3 2021 | $166,187,000 | +44.6% | 2,493,800 | +15.5% | 3.68% | +18.5% |
Q2 2021 | $114,912,000 | +109.6% | 2,160,000 | +71.0% | 3.11% | +105.2% |
Q1 2021 | $54,815,000 | -7.0% | 1,263,300 | +11.3% | 1.51% | -20.9% |
Q4 2020 | $58,952,000 | +99.5% | 1,135,000 | +25.5% | 1.91% | +39.6% |
Q3 2020 | $29,556,000 | -8.7% | 904,119 | +34.0% | 1.37% | -34.0% |
Q2 2020 | $32,389,000 | – | 674,487 | – | 2.08% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Paradigm Biocapital Advisors LP | 300,434 | $25,254,000 | 7.21% |
TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,628,409 | $220,944,000 | 6.56% |
Avidity Partners Management LP | 2,715,000 | $228,223,000 | 4.84% |
Matrix Capital Management Company, LP | 4,349,279 | $365,600,000 | 4.07% |
Affinity Asset Advisors, LLC | 117,500 | $9,877,000 | 3.59% |
Integral Health Asset Management, LLC | 120,000 | $10,087,000 | 2.79% |
Ghost Tree Capital, LLC | 80,000 | $6,725,000 | 2.41% |
Ikarian Capital, LLC | 191,140 | $16,067,000 | 2.39% |
Tri Locum Partners LP | 23,632 | $1,987,000 | 0.78% |
Eventide Asset Management | 529,000 | $44,468,000 | 0.57% |